Non-genetic specialists' experiences ordering chromosomal microarrays by Davis, Amy E
 NON-GENETIC SPECIALISTS’ EXPERIENCES ORDERING CHROMOSOMAL 
MICROARRAYS 
 
 
 
 
 
 
 
 
by 
Amy Elizabeth Davis 
BSc in Microbiology and Immunology, University of British Columbia, Canada, 2012 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of 
Master of Science 
 
 
 
 
University of Pittsburgh 
2016 
 
 
 
 ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
This thesis was presented 
 
by 
 
Amy Elizabeth Davis 
 
 
It was defended on 
April 11, 2016 
and approved by 
Committee Member: Andrea L. Durst, DrPH, LCGC 
Assistant Professor, Assistant Director, Genetic Counseling Program 
Human Genetics 
Graduate School of Public Health, University of Pittsburgh 
 
Committee Member: Roxanne Acquaro, MS, LCGC 
Lab Utilization Management 
Children’s Hospital of Pittsburgh of UPMC 
 
Committee Member: Ada O. Youk, PhD 
Associate Professor 
Biostatistics, Epidemiology, and Clinical & Translational Science 
Graduate School of Public Health and School of Medicine 
University of Pittsburgh 
 
Committee Co-Chair: Jodie Vento, MGC, LCGC 
Manager, Center for Rare Disease Therapy 
Manager, Brain Care Institute 
Genetic Counseling Supervisor, Laboratory Services 
Children’s Hospital of Pittsburgh of UPMC 
 
Committee Chair: Robin E. Grubs, PhD, LCGC 
Assistant Professor, Director, Genetic Counseling Program 
Human Genetics 
Graduate School of Public Health, University of Pittsburgh 
 
 
 
 iii 
Copyright © by Amy Davis 
2016 
 iv 
 
ABSTRACT 
Chromosomal microarray (CMA) is a first-tier clinical diagnostic test for individuals with 
developmental delay or intellectual disability, autism spectrum disorder, or multiple congenital 
anomalies. Due to the limited number of genetics professionals in the United States, non-genetic 
specialists often find themselves in situations where a CMA is indicated for their patient, but an 
evaluation by a clinical geneticist is not required. Many studies have identified barriers that non-
genetic specialists experience when ordering genetic testing such as poor knowledge of genetics, 
cost of testing, uncertainty of genetic testing issues, and fear of discrimination. There are 
currently no studies investigating barriers that non-genetic specialists’ encounter when ordering 
CMA. A survey was distributed to neurologists, developmental pediatricians, cardiologists, and 
endocrinologists at the Children’s Hospital of Pittsburgh of UPMC. The results of this survey 
were analyzed using descriptive statistics. Results showed that 43.8% of participants were 
ordering CMAs less often than they believe would be beneficial for their patients. The majority 
of participants (93.8%) indicated that the most significant barrier to ordering CMA was lack of 
insurance coverage. Participants indicated that on average, 48.1% of insurance pre-authorization 
requests get approved, regardless of insurance policy. Approximately 50-70% of participants 
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indicated that they order CMA for the patient indications outlined in the 2010 American College 
of Medical Genetics consensus guidelines. Most respondents (88.9%) reported being comfortable 
ordering a CMA. Respondents indicated that they were comfortable providing pre-test 
counseling (83.3%) and routinely discuss some, but not all issues relevant to CMA. Although not 
every study participant reported working with a genetic counselor, almost all respondents agreed 
that genetic counselors would be valuable or very valuable throughout all aspects of ordering a 
CMA. The public health significance of this study is that CMA plays an important role in the 
diagnostic evaluation of a significant number of patients. Given the limited supply of genetic 
professionals, non-genetic specialists may increasingly be expected to order CMA, and may 
experience barriers that prevent the effective use of this test in relevant clinical situations. 
Therefore, it is important to understand potential barriers to allow for appropriate 
implementation of CMA. 
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1.0  INTRODUCTION 
Providing patients with a genetic diagnosis can be essential to developing the best 
management plan for their care. A genetic diagnosis can inform treatment options, patient 
prognosis, and disease recurrence risk within a family. A chromosomal microarray (CMA) is a 
genetic test that looks at gains and losses of DNA regions that are too small to be detected by 
traditional karyotype analysis, and can be a vital tool when making a genetic diagnosis. In 2010, 
the American College of Medical Genetics published a consensus statement indicating that CMA 
is a first-tier clinical diagnostic test for individuals with developmental delay or intellectual 
disability, autism spectrum disorder, or multiple congenital anomalies (Miller et al, 2010), 
thereby underscoring the clinical importance of this test for certain indications. There is currently 
a limited number of genetics professionals in the United States (American Board of Medical 
Genetics and Genomics, 2016; Mary Henderson at American Board of Genetic Counseling, 
personal communication, February 22, 2016); therefore, it can be expected that many non-
genetic specialists will find themselves in situations where their patients will benefit from a 
CMA, but may not need an evaluation by a clinical geneticist. Numerous studies have identified 
poor knowledge of genetics, cost of testing, uncertainty of genetic testing issues, and fear of 
discrimination as barriers that non-geneticists experience when ordering genetic testing 
(Klitzman et al., 2013; Duncan et al., 2007; Salm et al., 2014; Watson et al., 1999; Nippert et al., 
2011; Rosas-Blum et al., 2007; Reiff et al., 2013). This presents significant challenges when 
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there are many patients who could benefit from genetic testing, such as a CMA, and a limited 
number of genetics professionals to facilitate this testing. Additionally, some insurance 
companies are now requiring that pre- and post-test genetic counseling be provided to patients 
when a CMA is ordered (Cigna Medical Coverage Policy, effective 7/15/2016). The aim of this 
study was to evaluate the current experiences that non-genetic specialists have in a tertiary care 
academic hospital setting when ordering CMAs, in order to help identify barriers that need to be 
addressed to improve patient access to this valuable test. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 OVERVIEW 
2.1.1 Chromosomal Microarray 
A chromosomal microarray (CMA) is a genetic test that is used to identify 
submicroscopic chromosome rearrangements across the entire genome that cannot be detected 
using traditional karyotype analysis (Battaglia et al., 2013; Miller et al., 2010). Current CMA 
technology relies on oligonucleotide platforms and can detect deletions and duplications in DNA 
regions that are less than 1 Megabase pair (Mb) in size. Therefore, this test can have a resolution 
up to 1000 times higher than conventional karyotype analysis (Trakadis and Shevell, 2011; 
Coulter et al., 2011). CMAs are widely used across a variety of clinical settings including 
prenatal and pediatric specialty clinics to investigate whether or not there is a genetic etiology 
that explains a particular medical condition.  A genetic diagnosis can be essential to best manage 
patient care by informing treatment options, patient prognosis, and disease recurrence risk within 
a family.  
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2.1.2 Consensus Guidelines for the Use of Chromosome Microarray 
In 2010, the American College of Medical Genetics (ACMG) published a consensus 
statement indicating that CMA is a first-tier clinical diagnostic test for individuals with non-
syndromic developmental delay or intellectual disability (DD/ID), autism spectrum disorders 
(ASDs), or multiple congenital anomalies (MCA) not associated with a well-delineated genetic 
syndrome (Manning and Hudgins, 2010). Consensus guidelines were also released upon the 
culmination of two international workshops from the International Standard Cytogenomic Array 
(ISCA) Consortium (Miller et al., 2010). This consensus statement and the consensus guidelines 
underscore the clinical importance of CMA for these disorders, which are relatively common in 
the population. DD is clinically characterized as significant impairment in cognitive and adaptive 
functioning diagnosed before the age of 18 years, and ID is defined as an impairment with 
adaptive functioning which can range from borderline (an IQ of 75-85) to profound (IQ <20-25) 
(Battaglia et al., 2013; Miller et al., 2010).  The incidence of DD/ID is approximately 3% in the 
population (Battaglia et al., 2013; Miller et al., 2010). ASDs encompass a group of disorders that 
are characterized by impairments in social and cognitive functioning, and can co-occur with 
intellectual disability and/or other co-morbid features, such as epilepsy (Battaglia et al., 2013; 
Stobbe et al., 2014). Approximately 1 in 88 children have been diagnosed with some form of 
ASD, and the diagnosis rate has continued to increase over recent years (Stobbe et al., 2014). 
Understanding the etiology of these conditions is often elusive, and a clinical diagnosis is 
typically based on patient symptoms alone.  
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2.1.3 Benefits of CMA 
Various studies have examined the clinical detection rate of CMA for DD/ID, ASDs, 
and/or MCA, which ranges from 5-35% (Battaglia et al., 2013; Stobbe et al., 2014; Roberts et al., 
2014; Lay-Son et al., 2015; Coulter et al., 2011, Shin et al., 2015). Importantly, studies have 
shown that CMA results, both known pathogenic variants and variants of possible clinical 
significance, can influence medical management for patients (Coulter et al., 2011; Riggs et al., 
2014; Gannon et al., 2011). Variants of possible significance (VPS) have been defined as 
variants that include deletions or duplications that overlap with reported pathogenic 
deletions/duplications, deletions or duplications containing genes that are suspected in disease 
pathogenesis, or changes that involve a gene for which loss of one copy through deletion would 
imply that the person is a carrier for a recessive trait (Coulter et al., 2011). VPS are commonly 
referred to as a variants of unknown significance (VUS) in many clinical settings. Retrospective 
analyses that investigated CMAs ordered for all clinical indications revealed that for patients 
with abnormal pathogenic variants, results impacted clinical management over 50% of the time 
(Coulter et al., 2011). Changes in patient management also occurred over 30% of the time for 
individuals who were found to have a VPS (Coulter et al., 2011). Clinical action that was 
undertaken in these cases included specialist referral, imaging studies, additional diagnostic 
testing, and medication prescription (Coulter et al., 2011).  
Additionally, studies have hypothesized that ordering CMAs as a first-line genetic test 
can result in significant cost savings by avoiding additional testing required to make a genetic 
diagnosis (Coulter et al., 2011; Regier et al., 2010). Coulter et al. (2011) reported that over 88% 
of patients who had a CMA that identified a positive result (pathogenic variant or VPS) 
previously had other genetic, metabolic, and/or neurologic testing. Tests included karyotype, 
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Fragile X, Prader-Willi methylation studies, plasma amino acids, urine organic acids, various 
single gene tests, and a variety of other biochemical tests. These tests identified a patient 
diagnosis in approximately 13% of cases, suggesting that ordering a CMA initially would be a 
cost-effective approach to finding a diagnosis for these patients (Coulter et al., 2011). Another 
study used decision analytic modeling to evaluate the cost-effectiveness of ordering CMAs as a 
first-line test for patients with intellectual disability (Regier et al., 2010). This analysis showed 
that based on cost and clinical detection rate, CMAs provide better value for the cost of testing 
compared to conventional karyotype analysis (Regier et al., 2010). Value was determined based 
on the trade-off between cost and clinical effectiveness, and cost of testing used in the modeling 
was determined by the fee schedule from the British Columbia Ministry of Health Services. In 
this scenario, CMAs cost $217 more than conventional karyotype analysis, however, CMAs 
yielded 8.2 diagnoses more per 100 patients tested. If decision makers were willing to pay 
$4,550 for an additional diagnosis, ordering a CMA as a first line test to diagnose individuals 
with ID would be more cost effective than ordering a conventional karyotype followed by 
additional testing required to make a diagnosis.  (Regier et al., 2010).  
 
2.2 PHYSICIANS EXPERIENCES ORDERING GENETIC TESTING 
2.2.1 Limited Number of Clinical Genetics Professionals 
A 2003 survey of the American Board of Medical Genetics certified geneticists was 
conducted to evaluate the state of the medical geneticist workforce (Cooksey et al., 2005). At the 
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time, there were approximately 3.5 MD clinical geneticists per one million people in the United 
States, and new entrants into the medical genetics profession were declining (Cooksey et al., 
2005). Today, there are approximately 1,594 MD clinical geneticists who are certified by the 
American Board of Medical Genetics and Genomics, and 3,623 genetic counselors who are 
certified by the American Board of Genetic Counseling. This totals approximately 5.0 MD 
clinical geneticists, and 11.3 genetic counselors per one million people in the United States 
(American Board of Medical Genetics and Genomics, 2016; Mary Henderson at American Board 
of Genetic Counseling, personal communication, February 22, 2016). To contrast this with 
another specialty, there are as many as 110 neurologists per one million people in urban areas in 
the United States (Avitzur, 2010). The limited number of clinical genetics professionals in the 
United States presents a problem as the knowledge and clinical applications in the field of 
genetics continues to expand.   
Many health-care providers who do not have specialized training in genetics may find 
themselves in situations where their patients could benefit from genetic testing, and might not 
need an evaluation by a clinical geneticist. Due to the complexity of interpreting genetic testing 
results, as well as the evolving landscape of genetic testing technologies, non-genetic specialists 
have not routinely ordered genetic testing. However, the benefits of genetic testing for certain 
patient indications challenges the idea that clinical geneticists should be the only physicians who 
order this testing, particularly due to the limited size of the genetics professional workforce. In 
particular, physicians in specialties such as neurology, cardiology, and endocrinology often 
consider genetic testing in the evaluation of their patients. 
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2.2.2 Non-Genetic Specialists’ Experiences Ordering Genetic Testing 
Despite increasing accessibility of genetic testing, studies suggest that primary care 
clinicians and other types of health-care providers generally lack sufficient training and/or 
knowledge in genetics to explain the complexities of genetic testing and technology to patients 
(Collier, 2012). For example, a survey administered by Powell and colleagues revealed that only 
15% of physician participants felt prepared to answer questions related to direct-to-consumer 
genetic testing (Powell et al., 2012; Collier, 2012). Studies have identified poor knowledge of 
genetics, cost of testing, lack of time to provide genetic counseling, low comfort level with 
genetic counseling, and fear of discrimination, as barriers that non-geneticists experience when 
ordering genetic testing (Klitzman et al., 2013; Duncan et al., 2007; Salm et al., 2014; Watson et 
al., 1999; Nippert et al., 2011; Rosas-Blum et al., 2007; Reiff et al., 2013).  
In 2013, Klitzman et al. surveyed 220 internists from two academic medical centers 
regarding their utilization of genetic testing. Approximately 74% of individuals rated their 
knowledge of genetics as very/somewhat poor, and 87% of individuals rated their knowledge of 
genetic testing guidelines as very/somewhat poor. Approximately 80% of study participants 
indicated that more training should be required for physicians in a variety of areas including 
when to order genetic testing, how to counsel patients, and genetic test result interpretation 
(Klitzman et al., 2013).  Interestingly, the study showed that physicians were more likely to order 
genetic testing if they had a geneticist or genetic counselor to whom to refer patients. Physicians' 
perceived needs for training was not significantly associated with ordering a genetic test. This 
suggests that physicians with varying levels of knowledge about genetic testing are currently 
ordering genetic testing for their patients. 
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A survey of pediatric otolaryngologists investigated how often these non-genetic 
specialists’ order genetic testing for their patients with sensorineural hearing loss, and how 
comfortable they are providing genetic counseling and disclosing patient results (Duncan et al., 
2007). 71% of study participants reported explaining the limitations and benefits of genetic 
testing to families, while 24% of individuals preferred to refer patients with sensorineural 
hearing loss directly to genetics professionals. With regards to results disclosures, 59% of 
pediatric otolaryngologists reported disclosing positive genetic test results, whereas 66% 
reported disclosing negative genetic test results. Nearly a third of participants stated that they 
schedule extra time to disclose both positive and negative results, whereas 15% of participants 
indicated that they only schedule extra time to disclose positive test results. For disclosing a 
positive result, 28% of physicians said that they refer patients to genetics professionals whereas 
18% of physicians refer patients to a genetics clinic for disclosing both positive and negative 
results. For those individuals who did not order genetic testing themselves, 74% said they 
preferred to have a genetics expert order and explain the testing. Other reasons for not ordering 
genetic testing included insufficient time to obtain consent, and limited knowledge regarding 
testing that did not allow physicians to properly obtain informed consent or explain the results to 
families. 
A study that surveyed neurologists and psychiatrists to ascertain their knowledge, 
attitudes, and behaviors involving genetic testing for neurodevelopmental and neurodegenerative 
disorders revealed that only 33% of respondents felt confident about how to order genetic testing 
and where to send genetic tests (Salm et al., 2014). Of the individuals who had previously 
ordered genetic testing, 74% reported that they could use more training in how to interpret test 
results. The majority of respondents (68% of those who had ordered tests and 55% of those who 
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had not) indicated that genetic testing should be performed more often in their specialty. This 
suggests that barriers exist that affect how often non-genetic specialists order genetic testing for 
their patients. Evidently, confidence in how to order and where to send tests significantly 
impacted ordering behaviors. Providers also indicated that they had concerns about genetic 
testing potentially causing psychological harm for their patients, and that lack of privacy of 
genetic data could possibly lead to patient discrimination. 
These studies propose that non-genetic specialists recognize the benefits of certain 
genetic tests, but can have insufficient knowledge about genetic testing and interpretation of test 
results, which can make pre-test counseling and consenting a patient within their specialty 
difficult. Additionally, many physicians lack the time required to thoroughly review information 
about genetic testing with patients, and address their possible questions. These issues present 
significant challenges when there are many patients who could benefit from genetic testing, such 
as a CMA, and a limited number of trained genetics professionals to facilitate this testing. 
2.2.3 Additional Barriers When Ordering CMA 
Although ACMG published the 2010 consensus statement that recommended CMA as a 
first-tier clinical diagnostic test for individuals with non-syndromic DD/ID, ASDs, or MCA, 
physicians have encountered difficulties when trying to obtain insurance pre-authorization for 
this test (Hughes, 2010; Riggs et al., 2014). In 2011, Riggs et al. surveyed members of the 
National Society of Genetic Counselors (NSGC) and the ACMG regarding their experiences 
ordering CMAs for their patients (Riggs et al., 2014). Only 18% of these genetics professionals 
reported ordering CMA testing every time it was indicated. The most common reason for not 
ordering this test for certain patients was lack of insurance coverage. Over 70% of study 
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participants indicated that they had received denial from insurance companies when ordering this 
test. The main reason was that insurance companies considered this test to be “experimental.” An 
additional reason included that testing was considered to not be medically necessary due to a 
lack of impact on the patient’s clinical management.  
If a substantial number of genetics professionals are receiving denials from insurance 
companies for CMA, it is important to consider how the insurance pre-authorization process 
affects non-genetic specialists when they want to order CMAs for their patients. Typically, this 
process involves writing a letter of medical necessity to the insurance company describing why a 
CMA is medically necessary for a patient, followed by possible appeal letters if the letter of 
medical necessity is declined.   It is unclear for which indications CMA was being ordered in the 
Riggs et al. (2014) study, however, the participants (genetics professionals) commented that 
CMAs were indicated for these patients. Moreover, some insurance companies are now requiring 
that pre-test and post-test genetic counseling be provided to patients when a CMA is being 
ordered (Cigna Medical Coverage Policy, effective 7/15/2016). This requirement is particularly 
relevant for non-genetic specialists who may feel less comfortable or lack sufficient time to 
provide genetic counseling to their patients.  
The purpose of this study was to better understand the current experiences of non-genetic 
specialists who order CMA in a tertiary hospital setting. Previous studies have revealed many 
barriers that non-genetic specialists can encounter when ordering genetic testing; therefore, it is 
important to understand barriers that might exist for physicians in this context. Study results will 
allow for appropriate interventions to address potential barriers in order to improve access to 
CMA for those patients who would truly benefit from this genetic test.  
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3.0  MATERIALS AND METHODS 
3.1 SPECIFIC AIMS 
Aim 1: Assess non-genetic specialists’ perceived knowledge of CMAs to determine if 
lack of information can affect when CMAs are ordered for patients. 
 
Aim 2: Explore non-genetic specialists’ comfort level providing genetic counseling to 
patients, and how this affects the CMA result disclosure process. 
 
Aim 3: Ascertain non-genetic specialists’ experiences with insurance pre-authorization 
when ordering CMAs. 
 
Aim 4: Evaluate genetic counselor involvement with non-genetic specialists when 
ordering CMAs, in terms of education, results disclosure, and the insurance pre-authorization 
process. 
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3.2 SURVEY DESIGN 
The study and survey were approved as an expedited study by the Institutional Review 
Board of the University of Pittsburgh (PRO#15090294) (see Appendix B for the IRB approval 
form). The survey design was based upon a questionnaire used in a previous study that evaluated 
internists’ experiences ordering genetic testing (Klitzman et al., 2013). Dr. Klitzman and his 
research team gave this study permission to use their survey for the purposes of survey design. 
The survey was built using Qualtrics survey software. Questions assessed physicians’ comfort 
level ordering different types of genetic testing and providing genetic counseling when ordering 
CMA. Questions examined the process with which different types of CMA results are disclosed, 
when CMAs are ordered, how often CMAs are ordered, and factors that may limit how often 
CMAs are ordered. The survey also assessed how genetic counselors have been involved in cases 
when a CMA has been ordered by a non-genetic specialist, and asked questions regarding the 
insurance pre-authorization process for CMAs. The survey also included questions regarding 
demographic information. Survey responses were initially linked to each participant’s email to 
allow for possible follow-up studies, however, responses were assigned a code to anonymize the 
data prior to analysis. The questionnaire was reviewed by several non-genetic specialists at the 
Children’s Hospital of Pittsburgh of UPMC who provided feedback regarding survey content, 
including readability and relevance of each question. A copy of the survey can be found in 
Appendix A.  
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3.3 SURVEY DISTRIBUTION 
The link to the Qualtrics survey was emailed to all neurologists, developmental 
pediatricians, cardiologists, and endocrinologists at the Children’s Hospital of Pittsburgh of 
UPMC using emails from the UPMC email directory. Physicians were surveyed from these 
specialties as they were most likely to have ordered CMA regularly for their patients.  Therefore, 
the survey was sent to 67 non-genetic physicians in the specialties listed above. A recruitment 
letter was provided in the body of the email (Appendix A), and the survey was emailed a total of 
five times from December 2015 until February 2016. Department chairs were asked to remind 
physicians about the survey at their department meeting in February 2016. Survey data was 
collected and stored using Qualtrics. Survey data was initially linked to email identifiers, which 
were removed and stored in a separate document linking responses to email addresses, prior to 
data analysis. De-identified data was downloaded from Qualtrics and stored on a secure server at 
the Children’s Hospital of Pittsburgh with password protection. The document containing email 
identifiers was also stored on this secure server with password protection, and accessible to only 
PI and research staff. 
3.4 ANALYSIS OF RESULTS 
Descriptive analysis was performed for all survey questions. Of the 67 non-genetic 
specialists who received an email about the study, 67 (100%) of them opened the email. 21 of 
these individuals (31.3%) clicked on the survey link, and of those physicians who opened the 
survey, 16 (76.2%) responded to every question in the survey. Three of the individuals who 
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clicked on the survey link (14.3%) did not continue the survey after reading the consent 
information. Two additional individuals answered some of the survey questions, but did not 
complete the entire survey. One of these participants indicated that they do not order CMAs for 
their patients. 
Non-responders were not included in the analysis of each question. Therefore, analyses 
for the majority of questions were based on responses from the 16 participants who completed 
the entire survey. Some questions were analyzed based on responses from 17 or 18 individuals, 
which is indicated in the tables and figures for each question. 
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4.0  RESULTS 
4.1 DEMOGRAPHICS 
Of the 67 non-genetics specialists employed at Children’s Hospital of Pittsburgh of 
UPMC who were sent the survey, 16 (23.9%) completed the questionnaire. Of the 16 
respondents, 37.5% were neurologists (n=6), 18.8% were developmental pediatricians (n=3), 
12.5% were cardiologists (n=2), and 31.3% were endocrinologists (n=5). The majority of 
participants were female (75%), between the ages of 40-59 years (68.7%), and had completed 
their medical training prior to the year 2000 (68.7%). The survey response rate varied by 
specialty: 30% for neurology (6/20), 60% for developmental pediatrics (3/5), 6.7% for 
cardiology (2/30), and 41.7% for endocrinology (5/12). The average time to complete the survey 
(n=16) was 9 minutes and 12 seconds (range = 4 minutes and 49 seconds – 16 minutes and 38 
seconds). Table 1 shown below describes the demographic information of the 16 participants in 
the study who completed the entire survey.    
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Table 1. Demographic summary of participants. 
 Total (n=16 ) 
 n % 
Provider Specialty   
    Neurology 6 37.5 
    Developmental Pediatrics 3 18.8 
    Cardiology 2 12.5 
    Endocrinology 5 31.3 
Genetics Training   
    Conference and Lecture 8 50 
    Lecture only 4 25 
    Certificate 0 0 
    N/A 4 25 
Sex   
    Male 4 25 
    Female 12 75 
Age   
    20-29 0 0 
    30-39 2 12.5 
    40-49 6 37.5 
    50-59 5 31.2 
    60+ 3 18.8 
Completed Medical Training Decade   
    1960-1969 0 0 
    1970-1979 1 6.3 
    1980-1989 5 31.2 
    1990-1999 5 31.2 
    2000-2009 4 25 
    2010-2019 1 6.3 
    Still in training 0 0 
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Almost half of the study participants (43.75%) indicated that they order CMAs less often 
than they believe would be beneficial for their patients. This statistic was calculated by 
comparing survey responses for how often providers have a patient that they think would benefit 
from a CMA each month, and how often each provider orders CMAs each month. Nine 
providers indicated that they order CMAs as often as they think would be beneficial for patients, 
and seven providers indicated that they order CMAs less often than they think would be 
beneficial for patients. None of the respondents indicated that they order CMAs more often than 
they think would be beneficial for patients. Figure 1 illustrates how many times study 
participants typically order CMAs each month, by provider type.  
 
Figure 1. Number of CMAs ordered each month by participant and provider specialty (n=16). 
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4.2 BARRIERS TO ORDERING CMA 
Respondents were queried about potential barriers that prevent them from ordering 
CMAs for their patients. Survey responses that indicated “strongly agree” or “agree” were 
combined to represent those respondents who agreed with each question. Survey responses that 
indicated “strongly disagree” or “disagree” were combined to represent those respondents who 
disagreed with each quesiton.  Most respondents (93.8%) agreed that a lack of insurance 
coverage for genetic testing limited the number of CMAs ordered by non-genetic specialists. 
Participants also agreed that the patient’s concerns about costs (75%) and the provider’s 
concerns about costs (66.7%) prevented non-genetic specialists from ordering CMAs for their 
patients. 
 In terms of knowledge regarding CMA, 50% of respondents disagreed that insufficient 
knowledge/experience about genetic testing limited the number of CMAs they ordered, and 
62.5% of individuals disagreed that a lack of knowledge regarding how to order and where to 
send CMAs limited the number of CMAs they order in their practice. These results are shown in 
Table 2.  Non-reponses from participants were not included in the analysis of each question, and 
the number of responses for each question is listed in the table. 
 
 
 
 
 
 
 
 20 
Table 2. Factors limiting the number of CMAs ordered by non-genetic specialists. 
 Number of 
Respondents 
Agree Neutral Disagree 
Patient’s concerns about insurance 
discrimination 
16 6 
(37.5%) 
3 
(18.8%) 
7 
(43.8%) 
My concerns about insurance discrimination 15 7 
(46.7%) 
4 
(26.7%) 
4 
(26.7%) 
Patient’s concerns about costs 16 12 
(75%) 
1 
(6.3%) 
3 
(18.7%) 
My concerns about costs 15 10 
(66.7%) 
1 
(6.7%) 
4 
(2.7%) 
Lack of insurance coverage of genetic testing 16 15 
(93.8%) 
0 
(0.0%) 
1 
(6.3%) 
My insufficient knowledge/experience about 
genetic testing 
16 4 
(25%) 
4 
(25%) 
8 
(50%) 
My lack of knowledge of how to order/where 
to send tests 
16 3 
(18.8%) 
3 
(18.8%) 
10 
(62.5%) 
Lack of detailed family history available 16 1 
(6.3%) 
6 
(37.5%) 
9 
(56.3%) 
Language barrier 16 2 
(12.5%) 
3 
(18.8%) 
11 
(68.8%) 
Patient’s level of education 16 2 
(12.5%) 
3 
(18.8%) 
11 
(68.8%) 
Lack of clinical guidelines 16 3 
(18.8%) 
3 
(18.8%) 
10 
(62.5%) 
My lack of access to geneticists/genetic 
counselors 
16 3 
(18.8%) 
3 
(18.8%) 
10 
(62.5%) 
Other (please indicate) 0 
 
4.2.1 Knowledge 
Most respondents (88.9%) specified that they were somewhat or very comfortable 
ordering CMA, and 81.3% of participants agreed that they were confident about the process for 
ordering a CMA. One study participant commented “I would appreciate having a resource person 
come lecture to new hires, residents, fellows, staff”. Figure 2 describes how comfortable 
respondents are ordering different types of genetic testing. Those participants who indicated that 
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they did not order next generation sequencing panels or whole-exome sequencing were not 
included in the analysis.  
 
 
 
Figure 2. The percentage of respondents who feel somewhat or very comfortable ordering 
different types of genetic testing: karytoype (n=18), CMA (n=18), single gene testing (n=18), 
next generation sequencing panel (n=17), whole-exome sequencing (n=16). 
 
The most common patient indications for which participants ordered CMA were global 
developmental delay (68.8%), developmental delay and multiple congenital anomalies (68.8%), 
multiple congenital anomalies only (62.5%), developmental delay and seizures and multiple 
congenital anomalies (56.3%), Autism spectrum disorder (50%), developmental delay and 
seizures (50%), and seizures and multiple congenital anomalies (50%). Figure 3 demonstrates 
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the different patient indications for which repondents order a CMA. Due to issues with the 
Qualtrics software, participants were unable to specify a response for “other”. 
 
Figure 3. The percentage of respondents who order CMA for different patient indications 
(n=16). 
4.2.2 Collaboration with Genetics Professionals 
Most respondents (n=16) indicated that they referred patients for a genetics consult either 
once per month (43.8%) or once per week (43.8%). Respondents had fewer informal 
conversations with genetics professionals about their patients, typically once per month (60%), 
with some participants specifying that they do not have informal patient conversations with a 
genetics professional (13.3%).  
When comparing survey responses regarding how often non-genetic specialists referred a 
patient to genetics vs. the number of CMA ordered each month, it appears that study participants 
referred their patients to genetics more frequently when they ordered CMA more often. Due to 
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the low response rate in this study, there is limited statistical power to analyze this relationship, 
and investigate whether different types of non-genetic specialists refer their patients to a genetics 
professional more often. Table 3 summarizes how often respondents referred their patients to a 
genetics professionals and how often they ordered CMAs each month.  
 
Table 3. The number of genetics referrals made by non-genetic specialists compared with 
the number of CMA ordered each month (n=16). 
 
Number of CMA 
ordered each month 
Number of Genetics Referrals 
>1 per week 1 per week 1 per month 
0 0 
(0.0%) 
1 
(6.3%) 
1 
(6.3%) 
1-2 1 
(6.3%) 
2 
(12.5%) 
2 
(12.5%) 
3-5 0 
(0.0%) 
4 
(25.0%) 
2 
(12.5%) 
5-10 1 
(6.3%) 
0 
(0.0%) 
1 
(6.3%) 
10-15 0 
(0.0%) 
0 
(0.0%) 
1 
(6.3%) 
 
4.2.3 CMA Result Disclosure 
The majority of respondents (81.3%) indicated that they have disclosed a CMA result in 
the last 6 months (n=16). Out of all the study participants (n=17), most expressed that normal 
results are disclosed over the phone, either by the physician themselves (70.6%) or a physician 
extender (65%). An abnormal CMA result is most often disclosed by the physician themselves, 
either in person (76.5%) or over the phone (52.9%). An uncertain CMA result is also most often 
disclosed by the physician themselves, either in person (70.6%) or over the phone (65%). With 
regards to referring a patient to review their CMA result with a genetics professional, this 
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happens most often with an uncertain CMA result (58.8%) or an abnormal CMA result (52.9%). 
Participants also refer their patients with a normal CMA result to genetics (35.3%). In some 
instances, respondents indicated that they send a CMA result letter to their patient and/or primary 
care provider in addition to providing a genetics referral or disclosing the result over the phone. 
Table 4 summarizes the different ways that respondents disclose CMA results. 
 
Table 4. Disclosure method for different types of CMA results (n=17) 
Type of 
Result 
Result Disclosure Method 
In Person Over the Phone Referral to 
Genetics 
Other: 
Letter1 Physician Physician 
extender2 
Physician Physician 
extender2 
Normal 
 
8 
(47.1%) 
4 
(23.5%) 
12 
(70.6%) 
11 
(65%) 
6 
(35.3%) 
2 
(11.8%) 
Abnormal 
 
13 
(76.5%) 
2 
(11.8%) 
9 
(52.9%) 
1 
(5.9%) 
9 
(52.9%) 
1 
(5.9%) 
Uncertain 
 
12 
(70.6%) 
1 
(5.9%) 
11 
(65%) 
3 
(17.6%) 
10 
(58.8%) 
1 
(5.9%) 
1To the patient and/or primary care provider  
2Nurse, medical assistant 
 
 
 
4.2.4 Genetic Counseling 
The majority of study participants expressed being either somewhat or very comfortable 
providing pre-test counseling (83.3%) or post-test counseling for a normal CMA result (88.9%). 
Fewer respondents expressed either being somewhat or very comfortable providing post-test 
counseling for an abnormal CMA result (55.6%) or a variant of uncertain significance (61.1%). 
Figure 4 demonstrates how comfortable respondents are providing different types of genetic 
counseling for CMA.   
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Figure 4. Percentage of respondents who are comfortable providing different types of 
genetic counseling when ordering a CMA (n=18). 
 
 
Issues discussed most often during pre-test counseling (n=16) include different result 
outcomes (positive, normal, or uncertain result) (93.8%), test turn-around time (93.8%), and 
limitations of testing (87.5%). The issues that were discussed least often with patients included 
the possibility of disclosing family relationships such as non-paternity (6.3%), and test sensitivity 
(12.5%). Figure 5 describes how often study participants discuss different issues related to CMA 
testing with their patients when providing pre-test counseling for CMA. Due to issues with the 
Qualtrics software, participants were unable to specify a response for “other”. 
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Figure 5. The percentage of respondents who discuss various issues during pre-test 
counseling for CMA (n=16). 
 
 
Study participants indicated that genetic counselors are most often involved in patient 
care when providing post-test counseling for CMA (75.0%). Genetic counselors are also often 
involved in the insurance pre-authorization process (37.5%) and CMA result disclosure (37.5%). 
18.8% of respondents stated that genetic counselors are not involved in patient care when a CMA 
is ordered (n=16). Figure 6 describes how a genetic counselor has been involved in the care of 
patients seen by non-genetic specialists when a CMA has been ordered. 
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Figure 6. Genetic counselor involvement with non-genetic specialists when a CMA is 
ordered (n=16). 
 
All respondents agreed that genetic counselors would be valuable or very valuable when 
reviewing genetic testing options based on patient indication(s), pre-test counseling for CMA, 
and post-test counseling for CMA. The large majority of participants (93.8%) stated that genetic 
counselors would be valuable or very valuable in regards to the insurance pre-authorization 
process for CMA, and with CMA result interpretation. 
4.2.5 Insurance Pre-Authorization Process 
The majority of participants (87.5%) agreed that the insurance pre-authorization process 
is a barrier for patient care when ordering CMA (n=16). Respondents indicated that on average, 
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48.1% (range = 5-90%) of insurance pre-authorization requests get approved, regardless of 
insurance policy (n=15). All of the participants agreed that there is a significant difference in 
time spent on CMA insurance pre-authorization based on the patient’s insurance policy (n=15). 
Most respondents (77.0%) indicated that letters of medical necessity (LMN) for a CMA 
took 30 minutes or more for each patient (n=13), and 37.5% of respondents indicated that an MD 
is involved in writing the LMN (n=16). Many participants (87.0%) specified that administrative 
staff and/or nurses also write LMNs (n=16). The neurologists in this study specified that LMNs 
could take anywhere from 10 minutes to more than 30 minutes, whereas all of the developmental 
pediatricians, cardiologists, and endocrinologists responded that an LMN for CMA requires at 
least 30 minutes of their time.  
For those insurance pre-authorization requests that were declined, most participants 
(78.6%) indicated that appeals took more than 30 minutes for each patient (n=14). 50% of 
respondents indicated that an MD is involved in writing the appeal (n=16), and 31.3% of 
participants indicated that only the MD is involved in the appeal process (n=16).  
Table 5 displays how much time participants spent on CMA letters of medical necessity 
and appeals during the insurance pre-authorization process for each patient. Those participants 
who indicated “N/A” or did not respond to the related survey questions were not included in the 
analysis. One neurologist specified that he/she does not write LMN for CMA, but is involved in 
the appeal process. This participant was only included in the analysis for time spent on appeals. 
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Table 5. Average time spent on a CMA letter of medical necessity and CMA appeal per patient 
by provider specialty (n=14). 
 
Provider 
specialty 
Number of 
Respondents 
Time spent 
<10 
minutes 
10 
minutes 
20 
minutes 
30 
minutes 
>30 
minutes 
Neurology 
 
6 Letter of medical necessity (n=5) 
0 
(0.0%) 
1 
(20.0%) 
2 
(40.0%) 
1 
(20.0%) 
1 
(20.0%) 
Appeal (n=6) 
1 
(16.7%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(16.7%) 
4 
(66.7%) 
Developmental 
Pediatrics 
2 Letter of medical necessity 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(100.0%) 
Appeal 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(100.0%) 
Cardiology 1 Letter of medical necessity 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(100.0%) 
0 
(0.0%) 
Appeal 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(100.0%) 
0 
(0.0%) 
Endocrinology 
 
5 Letter of medical necessity 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(40.0%) 
3 
(60.0%) 
Appeal 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
5 
(100.0%) 
All specialties 14 Letter of medical necessity (n=13) 
0 
(0.0%) 
1 
(7.8%) 
2 
(15.4%) 
4 
(30.8%) 
6 
(46.2%) 
Appeal (n=14) 
1 
(7.1%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(14.3%) 
11 
(78.6%) 
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5.0  DISCUSSION 
5.1 SURVEY ANALYSIS 
5.1.1 Demographics 
The group of physicians who were surveyed in this study represent a specific subset of 
non-genetic specialists as they work at the Children’s Hospital of Pittsburgh of UPMC, which is 
a tertiary care academic hospital with a well-established clinical genetics division.  However, it is 
important to better understand experiences of non-genetic specialists in this setting, because 
barriers that prevent these physicians from ordering CMA for their patients likely affect non-
genetic specialists in other hospital settings.  The data from this survey showed that a sizeable 
number of study participants (43.75%) were ordering CMAs less often than they believe would 
be beneficial for their patients. This supports previous findings in the literature which suggest 
that barriers exist which prevent non-genetic specialists from ordering this genetic test, such as 
poor knowledge of genetics, cost of testing, lack of time to provide genetic counseling, low 
comfort level with genetic counseling, and fear of discrimination (Klitzman et al., 2013; Duncan 
et al., 2007; Salm et al., 2014; Watson et al., 1999; Nippert et al., 2011; Rosas-Blum et al., 2007; 
Reiff et al., 2013).  
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5.1.2 Knowledge 
Study participants reported having a good understanding of genetic testing which differs 
from previous findings in the literature (Klitzman et al., 2013; Salm et al., 2014; Powell et al., 
2012; Collier, 2012; Nippert et al., 2011). While these studies have shown that the large majority 
of non-genetics specialists rate their knowledge of genetics and genetic testing guidelines as poor 
(Klitzman et al., 2013; Salm et al., 2014), participants in this study reported having a good 
understanding of genetics and genetic testing, and indicated that they were comfortable ordering 
certain types of genetic testing.  In the Klitzman et al. (2013) study, findings showed that 
physicians were more likely to order genetic testing if they had a geneticist or genetic counselor 
to whom to refer patients. It is possible that the physicians who participated in this study feel 
more comfortable ordering genetic testing because there are genetics professionals within their 
hospital where they can refer their patients. 
Most participants stated that they were comfortable ordering a karyotype (94.4%), CMA 
(88.9%), and single gene testing (72.2%), with fewer participants stating that they were 
comfortable ordering next generation sequencing panels (41.2%) and whole-exome sequencing 
(25.0%). While there is limited information in the literature regarding physician’s perceptions 
about different types of genetic testing, participants in this study may feel less comfortable 
ordering next generation sequencing panels and whole-exome sequencing due to the increased 
complexity of the technology and potential results. For example, the clinical utility of whole-
exome sequencing can vary by patient, and there are unclear guidelines regarding when this test 
should be ordered (Volk et al., 2015). Non-genetic specialists may also feel unequipped to 
provide adequate informed consent for whole-exome sequencing due to the complexity of the 
testing (Pinxten and Howard, 2014). 
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Half of respondents did not believe that insufficient knowledge/experience about genetic 
testing limited the number of CMAs that they order, and most participants (81.3%) agreed that 
they were confident about the process for ordering a CMA. One study participant commented “I 
would appreciate having a resource person come lecture to new hires, residents, fellows, staff” 
which is congruent with findings in the literature where non-genetic specialists indicate that 
more training in genetics should be required for physicians (Klitzman et al., 2013; Salm et al., 
2014). While studies have shown that non-genetic specialists report having an insufficient 
understanding of genetic testing guidelines (Klitzman et al., 2013; Salm et al., 2014), most 
participants (62.5%) disagreed that lack of clinical guidelines is a barrier when ordering genetic 
testing. This may be due to the availability of the ACMG guidelines for CMA, or the 
accessibility of genetics professionals within the same center who can clarify when CMA is 
indicated for a patient. 
Study participants reported ordering CMA for indiciations outlined in the 2010 ACMG 
consensus statement and the 2010 ISCA Consortium consensus guidelines. These indications 
include global DD (68.8%), DD and MCA (68.8%), MCA only (62.5%), DD and seizures and 
MCA (56.3%), ASD (50%), DD and seizures (50%), and seizures and MCA (50%). While some 
physicians ordered CMA for individuals with seizures, this was always when other indications 
were present such as DD and/or MCA. CMA was never ordered for patients with seizures only. 
Therefore,  most respondents reported ordering CMA for the appropriate indiciations outlined in 
the ACMG guidelines. As expected, the cardiologists and endocrinologists who participated in 
this study were less likely to see individuals with the above indications compared to respondents 
who were neurologists or developmental pediatricians. These physicians indicated that they 
ordered CMA for patients with isolated short stature (25%), disorders of growth (25%), disorders 
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of sexual development (18.8%), a cardiac diagnosis (18.8%), or an isolated heart defect (6.3%). 
These indications have not been included in the ACMG guidelines for CMA suggesting that 
some studey participants may be less aware of the recommended patient indications for CMA. It 
is not clear based on the data if physicians ordering CMA for these indications encounter more 
insurance issues than the physicians who order CMA for the recommended indications. It is also 
uncertain whether or not the cardiologists and endocrinologists who did not participate in the 
study also order CMA for these indications, or if they chose not to participate because they do 
not see patients with DD/ID, ASD or MCA, and therefore do not regularly order CMA. It would 
be beneficial to administer the survey to more physicians in the future to better understand how 
often non-genetic specialists are ordering CMA for indications that are not listed on the 
consensus guidelines for CMA. 
5.1.3 Genetic Counseling 
Previous studies have demonstrated that non-genetic specialists feel uncomfortable 
providing genetic counseling, or lack sufficient time to provide adequate counseling (Rosas-
Blum et al., 2007; Watson et al., 1999). A study conducted by Duncan et al. (2007) revealed that 
71% of otolaryngologists who were surveyed provided genetic counseling to their patients, and 
discussed the benefits and limitations of genetic testing for sensorineural hearing loss. However, 
45% of study participants answered questions regarding recurrence risks incorrectly, or indicated 
that they did not know the answer to certain questions. Unlike these research findings, the 
majority of participants in this study reported being either somewhat or very comfortable 
providing genetic counseling for CMA.  
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The majority of respondents felt comfortable providing pre-test counseling for CMA 
(83.3%). In “A Guide to Genetic Counseling”, Uhlmann et al. (2009) describe the importance of 
discussing the following issues during pre-test counseling for genetic testing: how genetic testing 
will affect healthcare and life decisions, insurance implications of genetic testing, sensitivity and 
other test parameters, cost of testing, uses and limitations of test results, how testing will affect 
other family members at risk, and supportive resources. All of this information is important to 
help a patient and/or family determine whether they are interested in genetic testing, and how 
genetic testing could affect their child and other family members in the future. Results from this 
study showed that respondents routinely discuss a variety of issues during pre-test counseling 
including different result outcomes (positive, normal, or uncertain result) (93.8%), limitations of 
testing (87.5%), the cost of testing (62.5%), and the possibility of revealing incidental or 
unrelated findings (62.5%). Issues that were discussed less often include the possibility of 
disclosing family relationships such as non-paternity (6.3%), and test sensitivity (12.5%). While 
many of the issues included in recommended pre-test counseling guidelines (Uhlmann et al., 
2009) were often discussed, the possibility of disclosing family relationships was rarely 
discussed with patients. This type of conversation can be difficult to have with families, but it is 
essential to provide them with this information in case there is a risk that genetic testing would 
reveal information that would affect family relationships in a negative way. Other issues like the 
possibility of revealing incidental or unrelated findings were discussed by most participants, but 
almost 40% of participants did not discuss this issue during pre-test counseling for CMA. This 
suggests that additional training may be warranted to ensure that physicians understand potential 
result outcomes from CMA, and are comfortable communicating this information with their 
patients to ensure that patients are prepared for this type of information. It is uncertain whether 
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physicians prioritize issues to be discussed during pre-test counseling due to insufficient time to 
review all relevant issues. This data was not ascertained from the study. 
Most respondents also expressed feeling somewhat or very comfortable providing post-
test counseling for a normal CMA result (88.9%). Fewer respondents expressed either being 
somewhat or very comfortable providing post-test counseling for an abnormal CMA result 
(55.6%) or a variant of uncertain significance (61.1%). Study participants reported referring 
patients to a genetics professional for all CMA result types, most often for an uncertain CMA 
result (58.8%) or an abnormal CMA result (52.9%), and less often for a normal CMA result 
(35.3%). Most respondents indicated that they referred patients for a genetics consult either once 
per month (43.8%) or one per week (43.8%). These findings are consistent with results from 
previous research where non-genetic specialists reported disclosing a normal genetic test result 
more often than an abnormal genetic test result (Duncan et al., 2007). Non-genetic specialists 
have also indicated that they refer their patients to a genetics professional more often for an 
abnormal or uncertain result compared to a normal result (Duncan et al., 2007). 
With regards to working with a genetic counselor when ordering a CMA,  81.2% of 
respondents indicated that a genetic counselor is typically involved in the CMA ordering process, 
most often to provide post-test counseling (75.0%), as well as with the insurance pre-
authorization process (37.5%) and CMA result disclosure (37.5%). Although not every study 
participant reported working with a genetic counselor, all respondents agreed that genetic 
counselors would be valuable or very valuable when reviewing genetic testing options based on 
patient indication(s), providing pre-test counseling for CMA, and providing post-test counseling 
for CMA. Most participants (93.8%) also stated that genetic counselors would be valuable or 
very valuable in regards to the insurance pre-authorization process for CMA and with CMA 
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result interpretation. While these non-genetic specialists indicated that they value genetic 
counselors, it appears that they may not have the opportunity to work with them directly. This is 
likely due to the limited number of genetic counselors who are available to work with non-
genetic specialists at this medical center, as most of the genetic counselors see patients with 
clinical geneticists. 
5.1.4 Insurance Pre-Authorization Process 
While lack of knowledge about genetics and genetic testing guidelines, low comfort level 
providing genetic counseling, and lack of access to a genetics professional do not appear to be 
barriers for ordering CMA in this physician cohort, most respondents (93.8%) agreed that lack of 
insurance coverage for genetic testing can limit the number of CMAs ordered by non-genetic 
specialists. This finding is consistent with previous findings in the literature that suggest a large 
proportion of insurance pre-authorization requests for CMA are denied due to a lack of evidence 
that CMA will change medical management for the patient (Hughes, 2010; Riggs et al., 2014). 
Most participants (87.5%) agreed that the insurance pre-authorization process is a barrier for 
patient care when ordering CMA, and indicated that on average, 48.1% of insurance pre-
authorization requests get approved, regardless of insurance policy. This approval rate for CMA 
is low despite approximately 50-70% of respondents indicating that they order CMA for the 
appropriate patient indications outlined in the ACMG guidelines.  
All participants agreed that there is a significant difference in time spent on CMA 
insurance pre-authorization based on the patient’s insurance policy. Most respondents (77.0%) 
indicated that letters of medical necessity for a CMA took 30 minutes or more for each patient. 
For those insurance pre-authorization requests that were declined, most participants (78.6%) 
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indicated that appeals took more than 30 minutes for each patient. It does not appear that other 
studies have investigated how much time is required by physicians to write letters of medical 
necessity or appeals for genetic testing. Based on the results from this study, the insurance pre-
authorization process for CMA can take well over an hour per patient which is significant when 
these physicians have busy clinics and see many patients who could benefit from CMA. This 
could potentially lead to physicians ordering fewer CMAs, or lacking sufficient time to write an 
appeal within the potential time constraints required by insurance companies. Genetic counselors 
could help improve access to CMA by using their expertise to write both LMNs and appeals, 
thereby, saving valuable clinic time for these physicians. 
 Importantly, some insurance companies are now requiring pre-test and post-test genetic 
counseling for patients when a CMA is ordered (Cigna Medical Coverage Policy, effective 
7/15/2016). If these patients have DD/ID, ASD, and/or MCA, CMA will be covered by certain 
insurance companies when genetic counseling is provided, and insurance pre-authorization 
would not be required. For some insurance policies, genetic counseling can be provided by a 
certified medical geneticist, a certified genetic counselor, or a credentialed genetic nurse (Cigna 
Medical Coverage Policy, effective 7/15/2016). Respondents from this study reported being 
amenable to working with genetic counselors as they believe genetic counselors are valuable 
when ordering a CMA. Genetic counselors would be an asset for non-genetic specialists to 
provide genetic counseling when a CMA is ordered. Not only would working with a genetic 
counselor save physicians’ time, but genetic counselors also have the expertise to discuss 
difficult issues during pre-test counseling. In particular, only 6.3% of respondents indicated that 
they discuss the possibility of disclosing family relationships such as non-paternity during pre-
test counseling. Genetic counselors have experience conducting these challenging conversations 
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with families, and would be able to provide comprehensive pre-test counseling for these patients, 
which would increase access to CMA by following insurance company policies.  
5.2 PUBLIC HEALTH SIGNIFICANCE 
In recent years, precision medicine has become a national initiative with the ultimate goal 
of personalizing patient care in order to improve health outcomes. Genetic testing can contribute 
to personalized medicine by allowing healthcare providers to better understand how an 
individual’s genetic information can impact their health. As genetic testing continues to expand 
and become relevant to many individuals, non-genetic specialists will increasingly be found in 
situations where they are expected to order genetic testing. It is essential to evaluate barriers that 
non-genetic specialists experience when ordering genetic testing, including barriers to accessing 
testing like the insurance pre-authorization process, as well as ethical barriers that affect 
individuals who are having genetic testing. For example, if comprehensive pre-test and post-test 
genetic counseling are not available to individuals, this raises ethical concerns that prevent 
patients from having a full understanding of genetic testing, and how it may impact their life. 
Genetic testing guidelines and policies are critical to ensure that individuals have access 
to genetic testing and are provided with appropriate genetic counseling. Genetic counselors have 
the expertise to provide pre-test and post-test genetic counseling, in addition to providing 
recommendations to insurance companies regarding insurance policies. Through collaboration 
with insurance companies, genetic counselors can provide the necessary expertise concerning 
different types of genetic testing to ensure equal access to testing for all individuals, in a way that 
is cost effective for insurers. 
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Additionally, it is essential that genetics professionals invest time in educating non-
genetic specialists about genetic testing policies, and elements to be included in pre-test and 
post-test genetic counseling. This will help non-genetic specialists navigate through the genetic 
testing process in situations when there are a limited number of genetics professionals to order 
testing and provide genetic counseling for patients. 
5.3 LIMITATIONS OF THE STUDY AND FUTURE DIRECTIONS 
There were several limitations to this study. The overall response rate of the 
questionnaire was relatively low at 23.9% (16/67). Study recruitment using predominantly email 
did not appear to be an effective way to recruit physicians for study participation. Previous 
studies have shown that physician response rate for online surveys is typically lower than the 
response rate for other types of research participants at 35-44% (Cunningham et al., 2015; 
Martins et al., 2007). It is unclear whether or not low response rate was due to insufficient time 
to complete the survey, or if physicians felt that their responses would be less relevant if they do 
not order CMA often. One respondent had filled in part of the survey, and then specified that 
he/she does not order CMAs. Due to the low response rate, it was not possible to compare data 
between different types of non-genetic specialists. 
 Non-genetic specialists who were surveyed work in a tertiary care academic hospital, 
and have access to genetics professionals. Most respondents were neurologists or developmental 
pediatricians (56.3%), female (75%) and between the ages of 40-59 years (68.7%). Therefore, 
these results are not generalizable to all non-genetic specialists in the United States. Fellows and 
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residents were not included in the study, and it would be interesting to better understand their 
experiences ordering CMA.  
In the future, it would be important to improve the recruitment strategy and increase the 
response rate. This could be accomplished by allocating 10-15 minutes in departmental meetings 
to complete a paper copy of the survey for those physicians who are interested. A study by 
Martins et al. (2007) demonstrated that follow-up telephone calls with physician study 
participants who had been sent an electronic survey increased the response rate from 44% to 
71%. Follow-up telephone calls could also be attempted in future studies to see if this improves 
the response rate. 
The wording of certain questions could be improved to better capture the data. For 
example, some survey questions asked how often participants refer their patients to genetics, 
while additional questions asked how different types of CMA results are disclosed, which 
included disclosure by a genetics professional. Sometimes it was reported that a genetics 
professional disclosed a CMA result when the patient was not referred to genetics. Exploring this 
discrepancy could provide valuable data.  For the purposes of the data analysis, information 
about the number of genetics referrals was based on whether or not a respondent indicated that 
they made a genetics referral for different types of CMA results. These questions would need to 
be edited to better understand how genetics professionals are involved when CMA results are 
disclosed. Due to technical problems with the Qualtrics software, certain questions did not allow 
participants to specify an answer when they selected “other” as a response. This issue would 
need to be resolved in a future study. 
It would be interesting to include more knowledge-based questions in a future study. 
Most of the questions assessing physician knowledge in this study were based on self-reporting, 
 41 
and it is unclear if this is an accurate way to measure physician knowledge regarding CMA. 
Most participants indicated being comfortable providing pre-test counseling for CMA, however, 
some did not discuss important issues that are recommended to be reviewed with patients during 
the pre-test counseling process. Therefore, although physicians reported being comfortable 
ordering CMAs, it would be important to ask additional questions that are not based on self-
reporting to evaluate physician knowledge. This would provide a better understanding of 
whether knowledge of CMA affects when a CMA is ordered, and determines the type of 
information discussed with patients during the pre-test and post-test counseling process. 
Finally, it would be interesting to survey non-genetic specialists who do not work in a 
tertiary care academic hospital to see what their experiences have been when ordering CMA. 
Knowledge about genetic testing and comfort level providing genetic counseling could be 
assessed for those physicians who do not work closely with genetics professionals, or are unable 
to easily refer their patients to a genetics clinic within their center. This additional information 
would enhance the understanding of non-genetic specialists’ experiences ordering CMA to 
inform insurance policies and improve access to this test. 
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6.0  CONCLUSION 
 Non-genetic specialists who work in a tertiary care academic hospital were surveyed to 
better understand their experiences ordering CMA. Survey answers were analyzed using 
descriptive statistics. The majority of study participants reported being knowledgeable about 
genetics and genetic testing guidelines, and most participants felt comfortable ordering genetic 
testing, and providing genetic counseling when a CMA is ordered. The majority of respondents 
agreed that the insurance pre-authorization process is the greatest barrier when ordering CMA. 
Most respondents have worked with genetic counselors when a CMA was ordered, and agree 
that a genetic counselor would be valuable or very valuable throughout the entire CMA ordering 
process. 
 These results will be useful to insurance companies who are developing policies to 
streamline the pre-authorization process for CMA requests. Most non-genetic specialists in this 
clinical setting are aware of the clinical indications for CMA, and feel comfortable working with 
a genetic counselor or providing pre-test and post-test genetic counseling themselves when this 
test is ordered.  
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APPENDIX A: STUDY SURVEY 
A.1 RECRUITMENT LETTER  
Study Title: Non-Genetic Specialists’ Experiences Ordering Chromosomal Microarrays 
 
To Whom It May Concern: 
You are being asked to participate in a research study to learn more about non-genetic 
specialists’ experiences ordering chromosomal microarrays (CMAs). You have been contacted 
because you are a neurologist, developmental pediatrician, cardiologist, or endocrinologist 
employed by the Children’s Hospital of Pittsburgh. 
You will be asked to complete an online survey inquiring about your experiences when 
ordering CMAs, including counseling patients, result disclosure, and the insurance pre-
authorization process. Completing this survey will take approximately 10 minutes of your time. 
Should you choose to participate in this study, your UPMC email address will be documented. 
Survey responses will be linked to your email address to allow for a possible follow-up survey in 
the future. Your responses will be stored in a password protected database, and will only be 
accessible to the principal investigator and research team. You may be contacted in the future 
regarding participation in follow-up studies. More information about any follow-up studies 
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would be provided at the time of study recruitment, and you would have the choice whether or 
not to participate. 
Please see the following survey link for this study (Survey Link specific to each 
participant here). For more information, please contact Jodie Vento, study PI and genetic 
counselor at the Children’s Hospital of Pittsburgh (412-692-8641, Jodie.Vento@chp.edu) or 
Amy Davis, study co-investigator and genetic counseling Master’s student at the University of 
Pittsburgh (aed50@pitt.edu). Thank you for your time. 
Sincerely, 
 
Amy Davis 
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A.2 INFORMED CONSENT SCRIPT 
 
You are being asked to participate in a research study to learn more about non-genetic 
specialists’ experiences with ordering chromosomal microarrays. A chromosomal microarray 
(CMA) is a genetic test that analyzes deletions and duplications of DNA regions that are too 
small to be detected by traditional karyotype analysis. This survey is being administered to non-
genetic specialists at the Children's Hospital of Pittsburgh. 
 
If you are willing to complete the following survey, which will take approximately 10 
minutes of your time, you will be asked about your experiences when ordering CMAs, including 
counseling patients, CMA result disclosure, and the insurance pre-authorization process. 
Demographic information will be collected, and your email address will automatically be 
documented along with the survey data. Your answers will be saved as you complete the survey, 
and you can stop and return to the survey at any time. This survey cannot be completed on a 
mobile device.  
 
Your participation is entirely voluntary, and you can withdraw from this study at any 
time. Whether or not you decide to participate will have no impact on your employment status at 
the Children’s Hospital of Pittsburgh. There is no possible risk of breach of confidentiality 
associated with this project, nor are there any direct benefits to you. Your email address will be 
collected, and we may contact you in the future regarding participation in follow-up studies. You 
are not required to participate in any follow-up studies. All survey responses are confidential, 
and will be stored in a password protected database. Only the study PI, co-investigator, and their 
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study team will have access to identifiable data.  Authorized representatives from the University 
of Pittsburgh Research Conduct and Compliance Office may review your data for the purpose of 
monitoring the conduct of this study. This study is being conducted by the University of 
Pittsburgh and the Children’s Hospital of Pittsburgh. This study has been approved by the 
University of Pittsburgh Institutional Review Board. For more information on this study, please 
contact Jodie Vento, study PI and genetic counselor at the Children’s Hospital of Pittsburgh 
(412-692-8641, Jodie.Vento@chp.edu) or Amy Davis, study co-investigator and genetic 
counseling Master’s student at the University of Pittsburgh (aed50@pitt.edu).  
 
If you wish to withdraw from the study in the future, please contact Jodie Vento, study 
PI, and all responses that were collected will be destroyed.  
 
I understand that I may contact the Human Subjects Protection Advocate of the IRB 
Office, University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and questions.  
 
Do you agree to participate? 
□ Yes 
□ No 
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A.3 SURVEY 
 
1) How comfortable are you ordering the following types of genetic testing? 
 
 Very 
uncomfortable 
Somewhat 
uncomfortable 
Neither 
comfortable 
nor 
uncomfortable 
Somewhat 
comfortable 
Very 
comfortable 
N/A 
Karyotype 
 
□  □  □  □  □  □  
Chromosomal 
microarray 
(CMA) 
 
□  □  □  □  □  □  
Single gene 
testing 
 
□  □  □  □  □  □  
Next 
generation 
sequencing 
panel 
 
□  □  □  □  □  □  
Whole-exome 
sequencing 
□  □  □  □  □  □  
 
 
2) How comfortable are you in the following situations providing: 
 
 Very 
uncomfortable 
Somewhat 
uncomfortable 
Neither 
comfortable 
nor 
uncomfortable 
Somewhat 
comfortable 
Very 
comfortable 
N/A 
Pre-test counseling 
for a CMA 
 
□  □  □  □  □  □  
Post-test counseling 
for a normal CMA 
□  □  □  □  □  □  
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result 
 
Post-test counseling 
for an abnormal 
CMA result 
 
 
□  □  □  □  □  □  
Post-test counseling 
for an unclear CMA 
result (“variant of 
unknown 
significance”) 
□  □  □  □  □  □  
 
3) With regards to disclosing CMA results, please indicate how the following types of results are 
disclosed (check all that apply): 
Normal result 
□ Disclose in person 
□ Disclose over the phone 
□ Refer patient to genetics 
□ N/A 
□ Other (please specify) ________________ 
 
 
If checked “normal result - disclose in person”: 
 
Who discloses results (check all that apply): 
□ I do 
□ Physician extender (nurse, medical assistant) 
□ Genetics professional 
□ Other (please specify) ________________ 
 
If checked “normal result - disclose over the phone”: 
 
Who discloses results (check all that apply): 
□ I do 
□ Physician extender (nurse, medical assistant) 
□ Genetics professional 
□ Other (please specify) ________________ 
 
4) With regards to disclosing CMA results, please indicate how the following types of results are 
disclosed (check all that apply): 
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Abnormal result 
□ Disclose in person 
□ Disclose over the phone 
□ Refer patient to genetics 
□ N/A 
□ Other (please specify) ________________ 
 
 
If checked “abnormal result - disclose in person”: 
 
Who discloses results (check all that apply): 
□ I do 
□ Physician extender (nurse, medical assistant) 
□ Genetics professional 
□ Other (please specify) ________________ 
 
If checked “abnormal result - disclose over the phone”: 
 
Who discloses results (check all that apply): 
□ I do 
□ Physician extender (nurse, medical assistant) 
□ Genetics professional 
□ Other (please specify) ________________ 
 
 
5) With regards to disclosing CMA results, please indicate how the following types of results are 
disclosed (check all that apply): 
 
Uncertain result 
□ Disclose in person 
□ Disclose over the phone 
□ Refer patient to genetics 
□ N/A 
□ Other (please specify) ________________ 
 
 
If checked “uncertain result - disclose in person”: 
 
Who discloses results (check all that apply): 
□ I do 
□ Physician extender (nurse, medical assistant) 
□ Genetics professional 
□ Other (please specify) ________________ 
 
If checked “uncertain result - disclose over the phone”: 
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Who discloses results (check all that apply): 
□ I do 
□ Physician extender (nurse, medical assistant) 
□ Genetics professional 
□ Other (please specify) ________________ 
 
 
6) Which of the following issues do you routinely discuss with patients/families when ordering a 
CMA (check all that apply):  
□ Different result outcomes (positive, normal, uncertain result) 
□ Uncertain result may require parental samples for further interpretation 
□ Incidental/unrelated findings 
□ Non-paternity/disclosing family relationships 
□ Test sensitivity 
□ Limitations of testing 
□ Test turn-around-time 
□ Cost of testing 
□ I do not provide pre-test counseling 
□ I do not order CMAs 
□ Other (please specify): __________________________________ 
 
7) Have you disclosed CMA results in the last 6 months? 
□ Yes 
□ No 
 
8) How often do you have a patient who you think would benefit from a CMA? 
□ 0 patients per month 
□ 1-2 patients per month 
□ 3-5 patients per month 
□ 5-10 patients per month 
□ 10-15 patients per month 
 
9) How often do you order CMAs for your patients? 
□ 0 times per month 
□ 1-2 times per month 
□ 3-5 times per month 
□ 5-10 times per month 
□ 10-15 times per month 
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10) To what extent do you agree or disagree with the following statement: The following factors limit 
how many genetic tests, such as CMAs, I order in my practice: 
 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
 
Agree Strongly 
agree 
N/A 
Patient’s concerns about 
insurance discrimination 
 
□  □  □  □  □  □  
My concerns about insurance 
discrimination 
 
□  □  □  □  □  □  
Patient’s concerns about costs 
 
□  □  □  □  □  □  
My concerns about costs 
 
□  □  □  □  □  □  
Lack of insurance coverage of 
genetic testing 
 
□  □  □  □  □  □  
My insufficient 
knowledge/experience about 
genetic testing 
 
□  □  □  □  □  □  
My lack of knowledge of how 
to order/where to send tests 
 
□  □  □  □  □  □  
Lack of detailed family history 
available 
 
□  □  □  □  □  □  
Language barrier 
 
□  □  □  □  □  □  
Patient’s level of education 
 
□  □  □  □  □  □  
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Lack of clinical guidelines 
 
□  □  □  □  □  □  
My lack of access to 
geneticists/genetic counselors 
 
□  □  □  □  □  □  
Other (please indicate) 
________________________ 
□  □  □  □  □  □  
 
11) For what patient indication(s) do you order a CMA (check all that apply): 
□ Global developmental delay 
□ Isolated seizures 
□ Isolated speech delay 
□ Isolated short stature 
□ Down syndrome 
□ Autism spectrum disorder 
□ Isolated congenital heart defect  
□ Multiple congenital anomalies only 
□ Developmental delay and seizures 
□ Developmental delay and multiple congenital anomalies 
□ Seizures and multiple congenital anomalies 
□ Developmental delay, seizures, and multiple congenital anomalies 
□ Cardiac diagnosis (Long QT, Sudden death, DCM, HCM, VT) 
□ Disorders of sex development 
□ Disorders of growth 
□ I do not order CMAs 
□ Other (please indicate): ______________________________________ 
 
 
 
12) To what extent do you agree or disagree with the following statement: I am confident about the 
process for ordering a CMA: 
 
Strongly disagree Disagree Neither agree 
nor disagree 
Agree Strongly 
agree 
N/A 
□  □  □  □  □  □  
 
 If answered ‘strongly disagree’, please explain: 
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13) How often do you refer a patient for a formal genetics consultation?  
□ Almost every day 
□ More than once a week 
□ Once a week 
□ Once a month 
□ Never 
 
14) How often do you have an informal conversation with a genetics professional regarding one of 
your patients? 
□ Almost every day 
□ More than once a week 
□ Once a week 
□ Once a month 
□ Never 
 
15) Please indicate how a genetic counselor has been involved in the care of your patient when a 
CMA has been ordered (check all that apply): 
□ Informed consent and pre-test counseling prior to ordering the CMA 
□ Informal consult 
□ Insurance preauthorization 
□ Patient education while the CMA is in process 
□ CMA result disclosure 
□ Post-test counseling 
□ N/A 
 
 
16) How valuable do you think a genetic counselor would be in the following areas when ordering a 
CMA for a patient: 
 Not 
valuable 
Somewhat 
valuable 
Neutral Valuable Very 
valuable 
Review of genetic testing options 
based on patient indication(s) 
 
□  □  □  □  □  
Pre-test counseling   
 
□  □  □  □  □  
Insurance pre-authorization 
  
□  □  □  □  □  
CMA result interpretation  
 
□  □  □  □  □  
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Post-testing counseling □  □  □  □  □  
 
 
 
 
17) Approximately how much time is spent on CMA insurance pre-authorization per patient for the 
following tasks: 
 Less than 10 
minutes 
10 
minutes 
20 
minutes 
30 
minutes 
Greater 
than 30 
minutes 
N/A 
Letter of medical 
necessity 
 
□  □  □  □  □  □  
If insurance pre-
authorization is 
denied, time spent on 
appeals  
□  □  □  □  □  □  
 
 
 
18) Please indicate which member on your staff normally writes a letter of medical necessity for 
CMA (check all that apply): 
□ Administrative staff 
□ Nurse 
□ I handle letters of medical necessity 
□ Other (please specify) ________________ 
□ N/A 
 
19) Please indicate which member on your staff normally writes an appeal for CMA (check all that 
apply): 
□ Administrative staff 
□ Nurse 
□ I handle insurance appeals 
□ Other (please specify) ________________ 
□ N/A 
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20) To what extent do you agree or disagree with the following statement: There is a significant 
difference in time spent on CMA insurance pre-authorization based on the patient’s insurance 
policy: 
 
Strongly disagree Disagree Neither agree 
nor disagree 
Agree Strongly 
agree 
N/A 
□  □  □  □  □  □  
 
 
21) Regardless of insurance policy, on a scale of 0-100%, what percentage of CMA insurance pre-
authorization requests do you estimate usually get approved: _____%         □ N/A 
 
 
22) To what extent do you agree or disagree with the following statement: The insurance pre-
authorization process is a barrier for patient care when ordering CMAs: 
 
Strongly disagree Disagree Neither agree 
nor disagree 
Agree Strongly 
agree 
N/A 
□  □  □  □  □  □  
 
 
Physician demographics: 
23) Provider specialty 
□ Neurology 
□ Developmental pediatrics 
□ Cardiology 
□ Endocrinology 
□ Other (please specify) ______________ 
 
24) Please indicate any genetics training you have received (check all that apply): 
□ Conference 
□ Certificate 
□ Lecture 
□ Other (please specific): _________________ 
□ N/A 
 
25) Gender 
□ Male  
□ Female 
 
26) Age 
□ 20-29 
□ 30-39 
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□ 40-49 
□ 50-59 
□ 60+ 
 
27) Completed medical training decade: 
□ 1960-1969 
□ 1970-1979 
□ 1980-1989 
□ 1990-1999 
□ 2000-2009 
□ 2010-2019 
□ Still in training 
 
 
28) Thank you for taking the time to fill out our survey. We would appreciate if you could provide 
feedback on our survey and any suggestions for improvement: 
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APPENDIX B: IRB APPROVAL FORM 
 
University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
Memorandum 
    
To: Jodie Vento , MS 
From: IRB Office 
Date: 11/17/2015  
IRB#: PRO15090294 
Subject: Non-Genetic Specialists' Experiences Ordering Chromosomal Microarrays   
 
The University of Pittsburgh Institutional Review Board reviewed and approved the above 
referenced study by the expedited review procedure authorized under 45 CFR 46.110 and 21 
CFR 56.110.  Your research study was approved under: 
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45 CFR 46.110.(7) 
 
 The IRB has approved the waiver for the requirement to obtain a written informed consent. 
 
The risk level designation is Minimal Risk. 
Approval Date: 11/17/2015 
Expiration Date: 11/16/2016 
For studies being conducted in UPMC facilities, no clinical activities can be undertaken by 
investigators until they have received approval from the UPMC Fiscal Review Office. 
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated 
problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 
56.108(b)]. Refer to the IRB Policy and Procedure Manual regarding the reporting requirements 
for unanticipated problems which include, but are not limited to, adverse events.  If you have any 
questions about this process, please contact the Adverse Events Coordinator at 412-383-1480. 
The protocol and consent forms, along with a brief progress report must be resubmitted at least 
one month prior to the renewal date noted above as required by FWA00006790 (University of 
Pittsburgh), FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 
(Children’s Hospital of Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), 
FWA00003338 (University of Pittsburgh Medical Center Cancer Institute). 
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
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